Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE (REPLACE)

Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE in the Treatment of Critical Limb Ischemia Lesions in the Absence of a Suitable Autologous Vein

Open repair could be recommended in a first line of treatment to revascularize critical limb ischemia patients or performed in a second line of treatment in case of failure of endovascular repair. A good quality vein is one of the main factors that influence the clinical success of open revascularization for below-knee popliteal. In the absence of an suitable autologous vein, prosthesis such as polytetrafluoroethylen (PTFE) graft could be an option but demonstrated worse clinical and morphological results compared to autologous greater saphenous vein. Consequently, there is still a room for improvement in CLI patients in the absence of an suitable autologous vein in whom endovascular repair failed.

Recently, PTFE with heparin-bound to the luminal surface (Hb-PTFE) significantly reduced the overall risk of primary graft failure by 37%, in particular, risk reduction was 50% in femoropopliteal bypass cases in cases with critical ischemia (58% Primary patency for crude ePTFE versus 80% primary patency for PROPATEN at 1 year follow-up) (Lindholt, et. al. 2011).

Additionally, a weighted average from the literature suggests a 76% primary patency for below knee bypasses performed with PROPATEN at one year follow-up, whereas a published meta-analysis suggests a 59% primary patency for below knee crude ePTFE at one year follow-up. At two year follow-up using the same approach, the average primary patency for PROPATEN was 67% versus 43% for standard ePTFE.

The aim of this study is to assess PTFE with heparin-bound to the luminal surface as an alternative to crude PTFE in absence of good venous conduit in patients with CLI.

Study Overview

• Status: Completed
• Conditions: Ischemia Lesions
• Intervention / Treatment: Procedure: revascularization; Device: Propaten®; Device: Crude PTFE

Detailed Description

Patient inclusion in this study will be proposed 60 to 1-days period preceding the surgical procedure. The patient will be randomized in the crude PTFE or in the Propaten groups. Regarding the intervention, the technique used during the therapeutic procedure shall be left to the operator's discretion, except the type of the graft. Demographic, intraoperative and postoperative data will be collected prospectively. Patient will be assessed and followed up according a current care. The cost difference between both groups will be identified.

• Study Type: Interventional
• Enrollment (Actual): 228
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Angers, France, 49 933
    • Angers University Hospital
  • Besançon, France, 25 000
    • Besançon University Hospital
  • Bordeaux, France, 33000
    • Bordeaux University Hospital - Hôpital Pellegrin
  • Boulogne-Billancourt, France, 92100
    • Ambroise Paré university Hospital
  • Brest, France, 29200
    • Brest University Hospital
  • Clermont-Ferrand, France, 63 003
    • Clermont-Ferrand University Hospital
  • Dijon, France, 21079
    • Dijon University Hospital
  • Lille, France, 59037
    • Lille University Hospital
  • Lyon, France, 69003
    • Lyon University Hospital - Hopital Edouard Herriot
  • Marseille, France, 13005
    • Timone Hospital
  • Nancy, France, 54500
    • Nancy University Hospital
  • Nantes, France, 44800
    • Nantes University Hospital
  • Nice, France, 06000
    • Hôpital Pasteur
  • Paris, France, 75015
    • Hôpital Européen Georges Pompidou
  • Paris, France, 75018
    • Bichat hospital
  • Paris, France, 75014
    • Saint Joseph Hospital
  • Poitiers, France, 86000
    • Poitiers University Hospital
  • Reims, France, 51092
    • Reims University Hospital
  • Saint Etienne, France, 42270
    • Saint Etienne University Hospital
  • Strasbourg, France, 67091
    • Nouvel Hôpital Civil
  • Valenciennes, France, 59322
    • Valenciennes University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient ≥18 years
• Patient presented critical limb ischemia (Rutherford classification: 4-6)
• Indication of below the knee bypass with an artificial graft
• Absence of an suitable autologous vein
• Patient is affiliated to the Social Security or equivalent system
• Patient has been informed of the nature of the study, agrees to its provisions and has signed the informed consent form prior to any study related procedure
• Patient agrees to undergo all protocol required follow-up examinations and requirements at the investigational site

Exclusion Criteria:

• No atheromatous disease
• Female of child bearing potential
• Patient has a history of coagulopathy or will refuse blood transfusions
• Patient is receiving or scheduled to receive anticancer therapy for malignancy within 1 year prior to or after the procedure
• Severe concomitant disease with life expectation < one year
• Known allergy to heparin
• Indication for ipsilateral major amputation
• Patient is not able to give informed consent
• Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have become commercially suitable since then, are not considered investigational trials
• In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Revascularization by (Propaten)®; Revascularization by PTFE with heparin bonded luminal surface (Propaten)®	Procedure: revascularization; open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.; Device: Propaten®; Propaten®
Active Comparator: Revascularization by Crude PTFE	Procedure: revascularization; open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.; Device: Crude PTFE; Crude PTFE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary patency at 1 year:	It was defined as a patent graft without any intervention to open up or prevent a graft occlusion. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Technical success defined as a patent bypass without stenosis of the proximal and the distal anastomoses.	Stenosis was defined as >30% diameter stenosis noted on intraoperative arteriography.	2 years
Perioperative complications	defined as any general complications or local complications that caused or prolonged hospitalization and/or re-intervention, lymphorrhea of more than 3-days and post-operative paresthesia that required drugs. The general complications included death from any cause, MACE. Local complications included MALE, hematoma, active bleeding, local infection, thrombosis, delayed wound healing and false aneurysm	2 years
Primary sustained clinical improvement	defined as a wound healing and rest pain resolution for patients in CLI, without the need for repeated graft it self or anastomoses in surviving patients.	1, 12 and 24 months post procedure
Secondary sustained clinical improvement	defined as primary sustained clinical improvement including the need for repeated graft it self or anastomoses.	1, 12 and 24 months post procedure
Primary patency	defined as a patent graft without any intervention to open up or prevent a graft occlusion. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.	1 and 24 months post procedure
Major adverse cardiovascular events	defined as MACEs including all cardiac deaths, Q wave infarction, stroke	1, 12 and 24 months post procedure
MALE (Major Adverse Limb Event)-free survival rates in subjects with CLI randomized to Propaten vs. crude ePTFE.	MALE is defined as above-ankle amputation of the index limb or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/ thrombolysis).	1, 6, 12 and 24 months
Limb salvage defined as freedom from above-ankle amputation of the index limb		1, 12 and 24 months post procedure
Secondary patency	secondary patency in which graft patency is lost (occlusion) and restored by thrombectomy, thrombolysis, or transluminal angioplasty, and/or any problems with the graft itself or one of its anastomoses require revision or reconstruction. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.	1, 12 and 24 months post procedure
Assisted patency	: Assisted patency at 1, 12 and 24 months post procedure, in which patency was never lost but maintained by prophylactic intervention. Demonstrably patent graft should be by a duplex ultrasound color-flow scan.	1, 12 and 24 months post procedure
Death	Death (all cause)	1, 12 and 24 months post procedure
Ankle brachial index	Post-operative assessment (clinical, morphological, hemodynamic criteria)	1, 6, 12 and 24 months post procedure
Quality of life at inclusion, .	assessed according the EQ-5D-3L questionnaire	1, 3, 6, 9, 12, 15, 18 and 24 months
Cost utility analysis (CUA)	In CUA, the outcomes of an intervention are evaluated in terms of Quality-Adjusted Life-Years (QALYs). QALYs are a numerical index that encompasses both the length of life and the health-related quality-of-life.	2 years
cost-effectiveness analysis (CEA)	The Measure of outcome for CEA will be the number of Life Years Gained (LYG) at 2 years	2 years

Collaborators and Investigators

• Sponsor: Nantes University Hospital
• Collaborators: W.L.Gore & Associates
• Investigators: Principal Investigator: Yann Gouëffic, Pr, Saint Joseph hospital Paris

Study record dates

Study Major Dates

• Study Start (Actual): February 13, 2018
• Primary Completion (Actual): January 29, 2024
• Study Completion (Actual): January 29, 2024

Study Registration Dates

• First Submitted: January 16, 2018
• First Submitted That Met QC Criteria: February 5, 2018
• First Posted (Actual): February 12, 2018

Study Record Updates

• Last Update Posted (Actual): April 5, 2024
• Last Update Submitted That Met QC Criteria: April 4, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: vascular; heparin; vascular prostheses; ischemia lesions; critical limb ischemia lesions
• Additional Relevant MeSH Terms: Pathologic Processes; Ischemia
• Other Study ID Numbers: RC17_0205

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No